TOP TEN perturbations for 38597_f_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38597_f_at
Selected probe(set): 210423_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38597_f_at (210423_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.1856527Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):4.1825113Number of Samples:2 / 3
| Experimental | glioma study 17 (anaplastic astrocytoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.085868Number of Samples:2 / 2
| Experimental | LPS study 4 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
calcitriol study 7 (10nM; 18h) / vitamin A study 3 (10nM; 18h)
Relative Expression (log2-ratio):3.3427124Number of Samples:4 / 4
| Experimental | calcitriol study 7 (10nM; 18h) |
| Peripheral blood monocyte samples derived from blood of healthy donors and treated with 10 nM calcitriol (1alpha, 25-Dihydroxyvitamin D3; 1,25(OH)2D3) for 18 h. ATC code:, | |
| Control | vitamin A study 3 (10nM; 18h) |
| Peripheral blood monocyte samples derived from blood of healthy donors and treated with 10 nM ATRA (all-trans retinoic acid, biologically active form of vitamin A) for 18 h. ATC code:--- |
glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue
Relative Expression (log2-ratio):3.3272152Number of Samples:2 / 4
| Experimental | glioma study 17 (glioblastoma; unsorted) |
| Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. | |
| Control | non-tumor cortical tissue |
| Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses. |
myocardial infarction study 7 (validation) / normal vascular endothelium cell sample (validation)
Relative Expression (log2-ratio):3.2942114Number of Samples:23 / 25
| Experimental | myocardial infarction study 7 (validation) |
| Circulating CD146+ endothelial cells (CECs) isolated from patients with acute myocardial infarction (AMI) with or without ST segment deviation assigned to the validation dataset. Arterial blood was collected in the cardiac catheterization laboratory following the placement of an arterial sheath prior to introduction of any guide wires or coronary catheters. The samples were maintained at room temperature and processed within 36 hours of collection. CECs were enriched from whole blood using CD146+ immunomagnetic separation and enumerated using the CellSearch system. AMI patients met strict diagnostic criteria including chest pain symptoms with electrocardiographic evidence of ST-segment elevation of at least 0.2 mV in two contiguous precordial leads or 0.1 mV in limb leads in addition to angiographic evidence of obstructive coronary artery disease in the setting of positive cardiac biomarkers. Inclusion criteria: 18 - 80 years of age; reliable, cooperative and willing to comply with all protocol-specified procedures if consented; able to understand and grant informed consent; acute MI defined as: clinical history and symptoms consistent with acute MI AND elevated cardiac markers (CKMB, Troponin I or T) consistent with MI AND able to complete study enrollment (consent & blood draw) within 48 hours of presentation to the study site. Exclusion criteria: significant medical condition that in the investigator's opinion may interfere with the patient's optimal participation in the study. | |
| Control | normal vascular endothelium cell sample (validation) |
| Circulating CD146+ endothelial cells (CECs) isolated from healthy control patients assigned to the validation dataset. CECs were enriched from whole blood using CD146+ immunomagnetic separation and enumerated using the CellSearch system. Inclusion criteria: 18-35 years of age; reliable, cooperative and willing to comply with all protocol-specified procedures if consented; able to understand and grant informed consent. Exclusion criteria: previous history of coronary artery disease or MI; Diabetes; Peripheral arterial disease; Hypertension (>140/90 or on blood pressure medication); sickle cell disease; acute or chronic kidney disease; acute or chronic vascular conditions, not otherwise specified; active or history of inflammation of connective tissue and vascular structures (i.e. vasculitis, rheumatoid arthritis). |
HIV-associated neurocognitive disorder study 4 (ischemia) / normal genu sample
Relative Expression (log2-ratio):3.1782637Number of Samples:2 / 8
| Experimental | HIV-associated neurocognitive disorder study 4 (ischemia) |
| Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from patients with ischemia. The patients did not receive any antiretroviral therapy (ART). | |
| Control | normal genu sample |
| Postmortem brain samples of the centrum semiovale (deep white matter) at the coronal level of the genu of the corpus callosum from healthy subjects. |
thermal injury study 1 (0-3d) / normal skin tissue
Relative Expression (log2-ratio):3.041831Number of Samples:3 / 3
| Experimental | thermal injury study 1 (0-3d) |
| Burn wound margin samples of the skin 0-3 days post thermal injury. | |
| Control | normal skin tissue |
| Normal skin tissue sample. |
thermal injury study 1 (4-7d) / normal skin tissue
Relative Expression (log2-ratio):2.912507Number of Samples:3 / 3
| Experimental | thermal injury study 1 (4-7d) |
| Burn wound margin samples of the skin 4-7 days post thermal injury. | |
| Control | normal skin tissue |
| Normal skin tissue sample. |
B-ALL study 1 (hyperdiploid) / normal bone marrow sample
Relative Expression (log2-ratio):-2.870202Number of Samples:40 / 74
| Experimental | B-ALL study 1 (hyperdiploid) |
| Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype). | |
| Control | normal bone marrow sample |
| Non-leukemic and healthy bone marrow sample. |